Additionally, personalized medicine approaches must be developed to identify disulfidptosis‐sensitive subtypes (e.g., tumors with high SLC7A11 or WRC expression) and tailor specific induction strategies (e.g., using different inhibitors depending on the tumor's NADPH source). This evidence concerns the gene SLC7A11 and neoplasm.